Company and Stock Identity

How Siemens Healthineers Connects to the Public Market

Company structure
Public company
Market access
Direct listing: Frankfurt and Xetra: SHL.
Stock name
Siemens Healthineers AG
Ticker and exchange
Frankfurt and Xetra: SHL
Research focus
Separate AI-enabled equipment and software from the broader imaging, diagnostics, and Varian businesses, and use country-specific regulatory sources for individual product claims.

Siemens Healthineers is separately listed and remains majority owned by Siemens AG.

A current price is not available in the automated United States market snapshot. Use the named exchange or the company investor-relations page for current trading data.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Siemens Healthineers Investor Relations ... Investor relations

Siemens Healthineers publishes third-quarter 2026 results

The investor hub published the company report, presentation, and analyst materials for its third quarter of fiscal 2026.

Why it matters: AI product announcements can look important without showing up in the business. Quarterly filings give investors a place to look for orders, revenue, margins, or strategy that connect those products to company performance. Siemens Healthineers is diversified, so the AI story has to be separated from everything else it sells.

... Hologic ... Company source

Hologic wins a European patent ruling that pulls Siemens Healthineers mammography systems from three countries

Hologic announced on June 16, 2026 that the Unified Patent Court in Germany ruled on June 10, 2026 that Siemens Healthineers infringed European Patent EP 2 352 431, which covers focusing technology in the Hologic Envision platform. Hologic says the court granted an injunction against making, selling, marketing, using, importing or storing the MAMMOMAT B.brilliant systems in Germany, France and the Netherlands, ordered a recall and destruction of affected systems in those countries, required Siemens Healthineers to refund customers and cover logistics costs, and left past and future damages for the court to set. Essex Mitchell, chief operating officer at Hologic, gave the company statement. The release names Siemens Healthineers AG, Siemens Healthcare GmbH, Siemens Healthineers Nederland B.V. and Siemens Healthcare SAS as the parties, and does not mention AI.

Why it matters: This is a hardware and patent fight, not an AI story, and that is exactly why it matters to a buyer of imaging AI. Breast imaging AI runs on top of a mammography system, so a hospital in one of these three countries now faces a scanner being removed and a decision about what replaces it, which drags every connected software choice along with it. Only Hologic has published its account here, so the scope of the recall, any appeal, and the final damages are all still open. A buyer outside Germany, France and the Netherlands is not directly affected by this order.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Imaging, diagnostics, cancer care, AI, software, clinical applications, regulatory affairs, field service, and product work.

Qualification signal: A global medical technology company hires across regulated product, clinical, engineering, and service roles. The required credential belongs to the job and country, not to healthcare AI as one field.

Check current roles at Siemens Healthineers. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

Siemens Healthineers appears on 12 cleared products in the federal 510(k) record, across 4 device types.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources